WO2024241281 - MODIFIED VECTORS
National phase entry:
Publication Number
WO/2024/241281
Publication Date
28.11.2024
International Application No.
PCT/IB2024/055053
International Filing Date
24.05.2024
Title **
[English]
MODIFIED VECTORS
[French]
VECTEURS MODIFIÉS
Applicants **
CSL BEHRING L.L.C.
1020 First Avenue
King of Prussia, Pennsylvania 19406-0901, US
SEATTLE CHILDREN’S HOSPITAL D/B/A SEATTLE CHILDREN’S RESEARCH INSTITUTE
1900 Ninth Avenue
Seattle, Washington 98101, US
Inventors
AESCHIMANN, Florian
c/o 655 Elizabeth Street
Melbourne, Victoria 3000, AU
MONTELLESE, Christian
c/o 655 Elizabeth Street
Melbourne, Victoria 3000, AU
Priority Data
63/469,040
25.05.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2909 | |
| EPO | Filing, Examination | 25590 | |
| Japan | Filing | 590 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 13560 |
Total: 43223 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
This disclosure relates generally to viral vectors useful for gene therapy applications. In particular the disclosure relates to lentiviral vectors, especially lentiviral vectors comprising modified insulator sequences.[French]
La présente invention concerne de manière générale des vecteurs viraux utiles pour des applications de thérapie génique. En particulier, l'invention concerne des vecteurs lentiviraux, en particulier des vecteurs lentiviraux comprenant des séquences isolantes modifiées.